
In treating Type 2 diabetes zzso UK guidelines recommend zzso in obese and overweight patients, and either zzso or zzso in normal weight zzso Although other factors influence prescribing choice, a key objective in treating zzso is to lower plasma zzso There is little data on how zzso response to oral agents varies with body mass index zzso zzso we assessed current prescribing practice and effect of zzso on zzso response to zzso and zzso in a large population zzso zzso 

zzso was determined in zzso zzso patients on zzso or zzso zzso in zzso Patients were identified from the Diabetes zzso and Research in zzso Scotland zzso zzso In a linear regression, the effect of zzso and other zzso on drug response was assessed in zzso zzso patients zzso zzso or zzso between 1994 and zzso 

In zzso zzso was more likely to be used in obese than non-obese zzso zzso normal weight, zzso overweight and zzso obese patients were treated with zzso zzso response to zzso was not influenced by zzso zzso zzso zzso zzso was more effective in lowering zzso in those with a lower zzso zzso zzso zzso P zzso zzso although the clinical impact of this was zzso The zzso reduction in non-obese patients was similar to that in obese patients zzso zzso zzso P zzso zzso 

zzso response to zzso in non-obese and obese patients is similar, suggesting that an zzso zzso should not influence the choice of oral zzso Given the zzso benefits of zzso it should be used in more non-obese patients than is current practice in zzso zzso 

